|12 Months Ended|
Sep. 30, 2018
10. FDA REFUND
On August 29, 2018, the Company received notification from the Food and Drug Administration (“FDA”) that the Company was being refunded $818,343 of 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA’s review of the associated Suprenza applications. The Company recorded as other income in the statements of operations the $818,343 receivable from the FDA as of September 30, 2018. The Company received the refund in full on October 1, 2018.
The entire disclosure for financing receivables. Examples of financing receivables include, but are not limited to, loans, trade accounts receivables, notes receivable, credit cards, and receivables relating to a lessor's right(s) to payment(s) from a lease other than an operating lease that is recognized as assets.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef